KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Royalty Pharma (RPRX) EBITDA Margin: 2019-2025

Historic EBITDA Margin for Royalty Pharma (RPRX) over the last 7 years, with Sep 2025 value amounting to 70.11%.

  • Royalty Pharma's EBITDA Margin fell 6007.00% to 70.11% in Q3 2025 from the same period last year, while for Sep 2025 it was 65.22%, marking a year-over-year decrease of 291.00%. This contributed to the annual value of 57.10% for FY2024, which is 628.00% down from last year.
  • Latest data reveals that Royalty Pharma reported EBITDA Margin of 70.11% as of Q3 2025, which was up 93.37% from 36.26% recorded in Q2 2025.
  • Royalty Pharma's EBITDA Margin's 5-year high stood at 130.17% during Q3 2024, with a 5-year trough of -85.31% in Q4 2022.
  • For the 3-year period, Royalty Pharma's EBITDA Margin averaged around 61.45%, with its median value being 60.90% (2024).
  • In the last 5 years, Royalty Pharma's EBITDA Margin crashed by 11,196bps in 2022 and then skyrocketed by 18,814bps in 2023.
  • Royalty Pharma's EBITDA Margin (Quarterly) stood at 26.65% in 2021, then slumped by 11,196bps to -85.31% in 2022, then spiked by 18,814bps to 102.82% in 2023, then plummeted by 4,193bps to 60.90% in 2024, then crashed by 6,007bps to 70.11% in 2025.
  • Its last three reported values are 70.11% in Q3 2025, 36.26% for Q2 2025, and 94.01% during Q1 2025.